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Abstract
Cardiovascular disease is the primary cause of morbidity and mortality in 
chronic kidney disease (CKD) population, particularly in end stage renal disease 
(ESRD). This could be explained in part due to the presence of traditional cardio-
vascular risk factors, such as older age, hypertension, dyslipidemia and diabetes, 
but is also associated with nontraditional cardiovascular risk factors related to 
CKD, like inflammation, anemia, abnormal calcium and phosphate metabolism 
and extracellular fluid volume overload, which may contribute to intimal or medial 
wall arterial calcification. Vascular calcification (VC) is a dynamic process, result-
ing from the dysregulation of the balance of molecules that promote and those that 
inhibit this course. It is important for clinicians to both acknowledge and recognize 
the pathways and risk factors of VC in order to improve cardiovascular health in 
CKD patients. This chapter will focus on the biology of VC, the association with 
CKD, risk factor modification, screening and prevention of VC and cardiovascular 
disease in CKD patients.
Keywords: vascular calcification, cardiovascular disease, chronic kidney disease, 
mineral metabolism
1. Introduction
Vascular Calcification (VC) refers to the ectopic deposition of calcium phosphate 
crystals in arterial walls [1, 2]. This is a process that can be seen in all arteries with a 
distinction made based on the offended layer of the wall – medial or intimal – with 
different explaining mechanisms [3]. Besides vessel walls, other tissues like cardiac 
valves can also show calcifications [1, 4, 5].
In 1855, Virchow described the VC as “artery ossification”, precisely in patients 
with renal disease [3, 6]. More recent, studies showed the same findings in Egyptian 
mummies [7].
In fact, with current molecular knowledge, we understand that mineraliza-
tion of the tunica media, the type of VC associated with CKD and its mineral 
disturbances [8], occurs with trans-differentiation of muscle cells to bone cells, in 
a process one could call ossification [9, 10]. On the origin of those cellular changes, 
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several factors interact to put in motion a series of events that will result in an active 
promotion of mineral deposition [1, 11, 12].
VC increases with age [13] and it is associated with many diseases such as dia-
betes [14], cardiovascular diseases (CVD) [8, 15], some genetic diseases [2, 16] and 
particularly CKD [8, 17–19]. In the latter, VC is observed in early stages, progresses 
with the renal impairment and affects almost every dialysis patient [20], even in 
the absence of traditional risk factors of hypertension, obesity, dyslipidaemia and 
smoking [21, 22]. For calcification to happen, an unregulated state of bone ossifica-
tion induction and the loss of many molecules that are believed to be osteogenesis 
inhibitors, must occur [11, 12]. In CKD, the culprit appointed by many recent 
studies is another of its complications – the mineral disturbance [11].
Cardiovascular (CV) events are tightly related to the CKD population, with high 
incidence of sudden cardiac death, arrhythmia, congestive heart failure and stroke, 
corresponding to the most common cause of death, especially in dialysis patients [2, 
20, 23]. VC progression and severity [24] is directly associated with these CV events 
and its related mortality [21] due to arterial calcification and its consequences, 
like ventricular hypertrophy or micro-embolic disease [10, 23, 25]. This explains 
the high prevalence of cardiac events and mortality even in patients without the 
traditional cardio-vascular risk factors [8, 10].
Until now, no study came to the conclusion that VC directly causes CV events 
[26]. Moreover, VC has some features in common with arterial aggression leading 
to CVD [26, 27]. For that reason, there are still some who argue that VC is a conse-
quence and not the cause for CVD [28–30].
This chapter will focus on the biology of vascular calcification and the associa-
tion with chronic kidney disease.
2. The biology of vascular calcification
The calcification of the vasculature refers to the pathological deposition of 
phospho-calcium minerals in the arteries, leading to its stiffness [19] and thick-
ening, as a result of a complex interaction of factors [4, 23]. Regardless of that, 
phospho-calcium can spontaneously precipitate [31]. Oversaturation increases of 
those ions concentrations and acidic environment favors their precipitation with 
a formation of various intermediates minerals, gradually bigger, until the least 
soluble, hydroxyapatite (HA) which will then crystalize [32]. The deposition of 
this crystal, or nucleation process, occurs chiefly in the apoptotic cells [9, 17, 33] or 
in mineral containing vesicles [34], which will then release more calcium to extra-
cellular matrix (ECM), promoting more apoptosis when entering the neighboring 
cells, in a vicious cycle [32].
2.1 Calcification types
The histological location of that deposition and the pathobiology has made a 
distinction between types of calcifications [4, 35]. This phenomenon can arise in: 
i) the inner layer of endothelial and connective subendothelial tissue of arteries, ii) 
the medial muscular layer, iii) in the cardiac valves (resulting in valve sclerosis and 
stenosis) and iv) calcific uremic arteriolopathy, previously known as calciphylaxis 
[3]. These are the calcifications referring to the vascular system, of which we will 
focus on the first two. Besides VC, other extra-skeletal calcifications may happen 
[3, 36].
Atherosclerosis, an accumulation of calcium in the intimal layer of large and 
medium sized arteries, is observed following a long inflammatory process and as 
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a last stage of that series of events [23, 37, 38]. It involves the infiltration of macro-
phages in the epithelial and subepithelial connective tissue and the formation of a 
lipid plaque [3, 23]. Hence, it is related to dyslipidaemia, arterial hypertension and 
tabagism, but also with age [8].
In medial calcific sclerosis (MCS) or Mönckeberg’s medial arteriosclerosis, 
the target of calcification is the muscular medial layer of elastic or muscular arter-
ies, and posteriorly, fibrosis, stiffness and thickening ensues [36, 37, 39]. This form 
is widely related to mineral imbalance, and it is seen in diabetes, some rare genetic 
diseases [40] and strongly related to CKD [17, 37]. This is the form to which we will 
be referring to.
It is important to point out that atherosclerosis is due to inflammation and lipid 
deposition and for that depends on the so-called traditional CV factors (dyslipidae-
mia, arterial hypertension and tabagism) while medial VC does not [23, 41, 42]. In 
atherosclerosis, plaque calcification creates areas of different compliance [23, 39, 
43, 44]. It ultimately leads to plaque rupture and acute vessel obstruction and is 
more closely associated with an increase in mortality [23, 43, 45, 46].
The association of MCS and mortality was brought up by many studies but not 
yet proven to be a cause-effect [28, 29] and some opinions still diverge, as we will 
discuss ahead. Research efforts have improved our knowledge on the molecular 
mechanisms involved, showing a passive process of physicochemical reaction 
resulting in vesicles [17, 47]. As stated earlier, apoptotic debris are good mineral 
nucleation sites but extracellular vesicles (EV) are regarded as having much higher 
mineralization potential [48].
Cells capable of osteo-transdifferentiation include not only vascular smooth 
muscle cells (VSMC) in the media, but also miofibroblasts in the adventitia, 
pericytes under endothelial cells (related to atherosclerosis), multipotent vascular 
mesenchymal cells and cardiac valve interstitial cells [42, 49, 50]. EVs, originally 
termed matrix vesicles, are nanoparticles of cellular origin, heterogeneous in 
size, shape and content, with two origins: membrane budding or in an endosomal 
pathway where multivesicular bodies fuse with the plasma membrane and then 
releases to the ECM by the regulation of sphingomyelin 3 [1, 17, 47, 51]. These EVs 
are designated exosomes [1, 52]. These vesicles are known for many decades to be 
related to bone mineralization but only recently were identified in VC. Indeed, EV’s 
membrane have affinity to matrix proteins and, contrary to non-calcifying vesicles, 
contain phosphatidilserin (acidic phospholipid) and calcium-channel annexin fam-
ily molecules in the membrane, responsible for the vesicle’s release. Annexin-6 has 
been described as a regulator of VC in vivo [1, 37, 47, 53].
EV’s release is promoted by high levels of calcium and their calcifying potential 
depends on its altered content compared to normal vesicles, with lower calcifica-
tion modulating proteins – which we will analyze in detail later –, higher calcium 
and phosphate content, lipids, microRNAs, matrix metalloproteinases (MMP) for 
matrix digestion and alkaline phosphatase (ALP), which normally is not present 
in vascular tissue. ALP releases free inorganic phosphate (Pi) – enhancing more 
crystal formation [47].
The nucleation of HA begins inside the vesicles, with molding crystals’ size 
and shape, and continues with the of in the ECM. Even tough origin and release 
of EVs are still poorly understood, vesicles are regarded as nucleating foci for VC 
[52, 54].
2.2 Transdifferentiation of VSMC
The unregulated osteogenesis is owed to the influence of external and 
internal factors (age, inflammation, toxins, CKD or diabetes) that induce 
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transformation of VSMC to osteogenic cells responsible for a pathological 
mineralization [23, 37, 54, 55].
Gene silencing lead to the loss of contractile properties by the underexpres-
sion of α-smooth muscle actin (SMA) and smooth muscle protein 22 (SM2) – the 
de-differentiation of VSMCs – whereas the upregulation of several genes coding for 
bone-like cells, give VSMCs the osteogenic characteristics [48, 49, 56]:
• ALP – enzyme responsible for the increasing Pi availability needed for crystal 
formation. ALP in soft tissues is a marker of ectopic calcium deposits [49, 57].
• Collagen I – implicated in the ECM remodeling and HA deposition as 
described [58].
• Osteopontin (OPN) – it is a binding-calcium particle (preventing HA forma-
tion) and a pro-inflammatory agent. It is thought that the cleavage of OPN 
under osteogenic circumstances by MMPs, may disrupter its equilibrium 
rendering an inflammatory and angiogenic role and involved in proliferation 
and migration of calcifying VSMCs [59].
• Osteocalcin and Osteonectin – increased in calcifying cells but with role on 
VC yet to be demonstrated [3, 25].
• RANK-L – Receptor activator of nuclear factor ΚB ligand. RANK is a member 
of tumor necrosis factor (TNF) receptor family, expressed by osteoclasts and 
increased in medial VC where it promotes VSMC calcification (demonstrated 
in vitro). The mechanism is the upregulation of a pathway of transdifferentia-
tion. It also promotes osteoclast activity, responsible for osteoporosis [13].
2.3 Loss of calcification inhibitors
Along with the aforementioned change in phenotype, the loss of calcification 
inhibitors must take place concomitantly for the end-result of VC [58] These are 
referred as the calcifying protein inhibitors preventing HA harm to ECM and 
cells [37].
They are herein described:
• Matrix Gla Protein (MGP) – Vitamin K dependent protein (VKDP), 
expressed in several tissues and in VSMCs. The activated molecule has a 
glutamic γ-carboxylation [55]. In normal states, the carboxylate MGP binds 
and inhibits crystal formation and prevents osteoblastic transformation. The 
unbalance toward the uncarboxylated inactive form is present in VC and is 
assumed to be a procalcifying agent [47]. Because of its vitamin K dependence 
for the γ-carboxylation of glutamic residues, anti-cumarinic medications (anti-
vitamin K) may disrupt its normal quantities [58, 60].
• Gla-Rich Protein (GRP) – GRP is the newest member of the vitamin 
K-dependent protein (VKDP) family, first identified in sturgeon calcified 
cartilage and characterized by the presence of an unprecedented 15 puta-
tive calcium-binding Gla residues in human [61]. It is considered a negative 
regulator of osteogenic differentiation [62], a modulator of calcium availability 
in the ECM [61, 63], and an inhibitor of calcification in the CV [64] and 
articular systems [65]. GRP calcium binding properties [61, 66] and associa-
tion to calcification processes [61, 63–67] indicates that its function might be 
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associated with prevention of calcium-induced signaling pathways and direct 
mineral-binding to inhibit crystal formation/maturation. GRP is also involved 
in the mineralization-competence of VSMCs derived EVs and possibly associ-
ated with the fetuin-A/MGP calcification inhibitory system [64].
• Fetuin-A (Fet-A) – also known as α2-Heremans-Schimd glycoprotein, is 
a potent anti-calcification glycoprotein in circulation [34]. Binds crystals there-
fore preventing its growth and the formation of insoluble nanoparticles  
[68, 69]. The complexes formed with crystals – primary calciprotein particles 
(CPP-1) – are more easily eliminated by the reticuloendothelial system than 
normal calciparticles and with less toxicity to those cells [70]. The re-arrange-
ment of the CPP-1 in terms of form and crystal features will make a particle 
believed to be more cytotoxic and VC-inducing, called secondary CPP (CPP-2) 
[37]. Fet-A is linked with reduction of inflammatory response and oxidative 
stress produced by calcification. As seen, it is diminished in EVs responsible 
for VC [49]. Studies shown Fet-A to be decrease in serum of CKD patients, 
with age, restrictive diet, low weight and aerobic exercise [58]. Despite being 
phospho-calcium containers impeding its growth and deposition, CPPs are 
cytotoxic particles and in case of impaired elimination it is believed to be 
responsible for the inflammation state and premature aging seen on CKD.
• Osteoprogerin (OPG) – binds RANK-L preventing its binding to RANK and 
its effects: osteoclastic differentiation and medial calcification [58, 71].
• Pyrophosphate (PPi) – prevents the formation of phospho-calcium crystals in 
the extracellular environment [58, 71].
2.4 Regulation: Signaling pathways
Different, complex and not fully understood molecular pathways activate the 
changes described in the pathobiology of VC [4]. Many of those factors have more 
than one implication in VC and a lot of them interact with each other. There is a 
“perfect storm” [25, 49] behind VC. Hereby we analyze the mechanism and the 
signals involved with the onset of VC.
• Runx2/Cbaf – The transcriptional promoter activity of Runt-related tran-
scriptor factor-2, also known as Core-binding factor subunit 𝛼1, is responsible 
for the underexpression of muscle fibers causing the de-differentiation process 
of VSMCs [72]. Together with the downstream Osterix gene it is responsible 
for the upregulation of the aforementioned Osteocalcin, Osteopontin (OPN), 
Osteonectin, ALP, Collagen I, RANK-L and also sclerostin, since all of them 
have a binding site for cbaf in their genes/promoters [49, 58]. These promoters 
regulate genes involved with the cell cycle for lineage determination, interact-
ing in order to enhance osteoblastic/osteochondrogenic protein characteristics 
and osteogenic lineage commitment of the VSMCs [73]. This mechanism is 
related with age, CKD, diabetes type 2, inflammation and with toxins like 
uremic products [37, 72].
• Wnt pathway – in this signal transduction pathway, several glycoproteins 
(Wnts) are capable of activating specific membrane receptor complexes, 
responsible for the dephosphorylated stabilization of ß-catenin that leads to 
the intracellular signaling of transcription factors activation [13, 74]. Different 
receptors are involved but low-density related protein receptors (LRP) 5 and 
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6 were described as involved in the pathway resulting in activation of Runx2 
and Osterix by ß-catenin, in a way not yet clarified [13, 58]. There are many 
proteins to regulate Wnt cascade like sclerostin, which binds to the membrane 
receptor thus inhibiting it, and MSX-2 homeobox that promotes paracrine 
Wnt signals [13, 49]. It is also implied in the cell-cycle, proliferation, lineage 
commitment and regulation of apoptosis and its activation is related to TNF-α, 
oxidative stress and hyperphosphatemia [13, 58].
• The Bone Morphogenetic Protein-2 (BMP-2) – a cytokine of TGF-ß family and 
a mediator of VC. By activating its membrane receptor can activate (by phos-
phorylation) co-regulatory proteins of the Smad family and will put, together 
with Runx2, the cascade of events in motion [42, 58]. Both BMP-2 and BMP-4 
receptors can phosphorylate and activate that cascade toward osteoblastic/chon-
drocyte’s formation and prevent mesenchymal cells transformation in (normal) 
VSMCs or adipocytes. It is crucial for VC to happen, since neither BMPs nor 
Runx2 are able to put the osteogenesis machinery in motion alone [13, 58].
• TGF-ß – upregulated when elastosis develops, like BMPs, can promote the 
transducing of osteogenic genes with Runx2 activation [58].
• RANK/RANK-L/OPG pathway – the already mentioned TNF-α family 
receptor, RANK activation results in the activation of NF-𝜿B transcription 
factor. Involved in cellular responses to aggressions like free radicals, oxidized 
LDL cholesterol or some cytokines and it was linked to VC in some studies. It 
also increases BMP-4 expression and so, activates Runx2 [58]. As discussed, 
RANK-L is the activator of receptor RANK and OPG competes with RANK-L, 
preventing the pathway activation. So, RANK signaling depends on RANK-
L:OPG ratio but also indirectly of the regulatory factor Runx2, capable of 
promoting RANK-L expression [25, 71].
• ENPP1/PPi/ALP axis – as discussed, PPi opposes crystal formation whereas 
ALP is a crystal-promotor by hydrolysing PPi and making it a source of 
phosphor (Pi) [47]. In a complex interaction of several enzymes, PPi is formed 
by Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 enzyme (ENPP1) 
from adenosine triphosphate (ATP). Another membrane enzyme – Progressive 
Ankylosis Protein (ANK) – makes PPi available to the extracellular environ-
ment where it can prevent Pi to mineralize. An overexpression of ENPP1, ANK 
and ALP gives the continuous exaggerated production and release of PPi to the 
ECM, for posterior destruction by ALP [36, 47, 57, 58].
Vitamin D can induce such activity. ATP Binding Cassette Subfamily C member 
6 (ABCC6) and ecto-5′-nucleotidase (NT5E) genes encode for the intermediary 
enzymes in the formation and degradation of ATP to AMP and ultimately, adenos-
ine; These several enzymes are related to genetic calcifying diseases [58].
• Phosphate and calcium status – increased concentrations of these ions result 
in the formation of either crystals or nanoparticles with proteins, as referred. 
Transient or continuous elevated extracellular phosphate, in any form, has 
cytotoxicity consequences: it can lead to apoptosis because of ROS burden, an 
important calcifying event; and it can activate the digesting MMPs responsible 
for elastolysis [4, 13, 75]. Elevated calcium concentrations facilitate phosphate 
entry and is linked to calcification even in normal phosphoric quantities. Both 
calcium and Pi are related with Runx2 activation [13, 17, 47]. HA crystals, 
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nanoparticles or free phosphate can render the same results. In fact, it has been 
proposed that cell-internalized CPPs with low fetuin-A are the most common 
event and that they can be detected circulating in CKD patients’ blood, as they 
do not in healthy individuals [32].
• MicroRNAs (miRNAs) – regulate gene expression by targeting translated 
mRNAs and altering its traducing to proteins. EVs are known to have miRNAs 
and there have been new studies on this matter [47].
On the other hand, it is of notice that for the installation of VC, there is a role to 
be played by the concomitant loss of several osteogenesis antagonizing molecules, 
such as [58]:
• MGP, GRP and Fet-A – the carboxylated forms not only bind calcium but also 
inhibit BMPs impeding BMPs-BMP receptor activation.
• BMP-7 – apart from the other BMPs, it does not promote Runx2 but the 
expression of smooth muscle fibers, antagonizing the VSMC differentiation. 
Because of that, the loss of its action will possibly increase VC risk [58, 72].
• Sclerostin – a glycoprotein with expression promoted by Runx2 and OSX is 
not consistently associated with VC and its role is to be fully explained, but it 
was however identified as an inhibitor of the Wnt cascade in its signal activa-
tion by ß-catenin and therefore inhibiting osteogenesis [58].
• Adiponectin – an adipocyte’s hormone, restricts osteoblastic differentiation by 
1/p38 receptors signaling pathway [40].
A complex myriad of factors may offend the vessel wall’s cells such as: elas-
tolysis, cytokines, ROS, oxidized lipids, glucose, uremic molecules, BMPs and 
circulating calciprotein particles (CCPs). These will ignite signaling pathways like 
the Wnt pathway, resulting in the trans-differentiation of VSCM by the action 
Figure 1. 
Mechanisms of vascular calcification. ALP: Alkaline phosphatase; Fet-A: Fetuin-A; GRP: Gla-rich protein; 
MGP: Matrix Gla protein; OPN: Osteopontin; OPG: Osteoprotegerin; PPi: Pyrophosphate; RANK-L: Receptor 
activator of nuclear factor ΚB- ligand; VC: Vascular calcification; VSMC: Vascular smooth muscle cells. 
(Adapted from Dellegrottaglie et al. [28].)
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of transcription factor Runx2. Deposition of minerals is promoted in the matrix, 
either in vesicles or apoptotic bodies. As this occurs, a loss of calcification inhibitors 
will pose no obstruction to the process.
Ultimately, the stiffness caused by this remodeling of the medial layer will result 
in ventricular hypertrophy [19, 49].
Figure 1 resumes the before mentioned pathways and mechanisms implied in 
the vascular calcification process.
3. Vascular calcification in chronic kidney disease
Cardiovascular disease is the leading cause of death in patients with CKD, 
especially among those with end stage renal disease (ESRD) [76, 77]. This high 
cardiovascular risk may be in part due to excess VC [78, 79].
The prevalence of vascular calcification in CKD patients increases with progres-
sively decreasing kidney function and is greater than the general population [21, 
80]. In patients with estimated glomerular filtration rate (eGFR) less than 60 mL/
min/1.73 m2 and not on dialysis, VC is known to be present in 47 to 83%. In dialysis 
adult patients, coronary artery calcification (CAC) has been detected in 51–93% 
and valvular calcification in 20–47% [2, 5, 81].
Increased CV risk may be due to CAC, with remarkably high prevalence in 
patients undergoing dialysis [8, 76, 82, 83]. It can be said that 20-year-old patients 
in dialysis have the same CV mortality risk as 80–90 year-old non-diabetic and 
non-uraemic subjects [82]. This may be associated with dialysis vintage, the intake 
of supplemental calcium, particularly with calcium-containing phosphate binders, 
and the mean calcium-phosphorus ion product.
3.1 Clinical significance
The diagnosis of CKD–Mineral Bone Disease (MBD) includes the detection of 
extra-osseous calcification, such as arterial, valvular, and myocardial calcifica-
tion [5].
The clinical significance of vascular calcification depends on the site (ie, medial 
or intimal) and type of the affected arteries. Intimal calcification is associated with 
the formation and progression of atherosclerotic lesions and is associated with the 
development of plaques and occlusive lesions as in coronary artery disease, cerebro-
vascular disease, and peripheral vascular disease [9].
Tunica media calcification was initially considered to be clinically non-
significant [9]. However, it was later demonstrated in CKD and ESRD patients that 
was associated with decreased vascular distensibility and increased vessel stiffness 
and pulse pressure with consequent progression of intimal lesions [9, 11, 84–86]. 
London et al. conducted a study including 202 HD patients which showed that 
medial calcification had major impact on clinical outcome, being an independent 
prognostic marker for all cause and CV mortality in chronic HD patients indepen-
dently of classical atherogenic factors, with close association to time on HD [8].
3.1.1 Coronary artery calcification
Coronary artery calcification (CAC) is common and progressive in young adults 
with ESRD who are undergoing dialysis [21]. Some studies reveal an association 
between CAC and CVD in this population [80, 83].
Coronary artery calcification score, measured noninvasively by electron-beam 
computed tomography (EBCT), was found to be an independent predictor of overall 
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mortality in dialysis patients [87]. In one study with 39 patients undergoing HD, those 
with CAC had higher serum phosphorus concentrations, higher calcium–phosphorus 
ion product in serum, and their daily intake of calcium-containing phosphate- 
binding agents was nearly two times greater than those without calcification [21].
3.1.2 Large-vessel calcification
Calcification of aorta and other large arteries is associated with increased 
arterial stiffness. This will cause lack of distensibility, leading to hypertension and 
increased pulse pressure, both risk factors for left ventricular dysfunction and heart 
failure among CKD patients [85, 88].
3.2 Risk factors
The higher prevalence of traditional CV risk factors, such as older age, hyper-
tension, dyslipidemia and diabetes, and the presence of nontraditional CV risk 
factors related to CKD (anemia, abnormal calcium and phosphate metabolism, 
extracellular fluid volume overload, electrolyte imbalance) may explain the high 
occurrence of CVD and contribute to intimal or medial wall calcification in patients 
with kidney failure [28].
3.2.1 Demographic features and time on dialysis
Vascular calcification is associated with the increasing age and time on dialysis [21, 
89, 90]. A study with 134 patients on HD, peritoneal dialysis and with stage 4 CKD 
demonstrated that age and male gender were important determinants of VC [77, 91].
3.2.2 Mineral metabolism
Disorders of mineral metabolism may promote CV calcification, contributing to 
higher CVD and mortality in patients with kidney failure or ESRD. Several obser-
vational studies have noted an association between mineral and bone disorders with 
adverse outcomes, most notably with increased phosphate levels (increased risk of 
VC, cardiomyopathy, and mortality) [11, 22, 92, 93].
Hyperphosphatemia, uremia, hyperglycemia and other metabolites may initiate 
the process of VC by transforming vascular smooth muscle cells to a chondrocyte 
or osteoblast-like cell. In dialysis patients, this process is accelerated in the setting 
of the common presence of high calcium, high phosphorus, and abnormal bone 
remodeling [91].
3.2.2.1 Hyperphosphatemia and hypercalcemia
Epidemiological studies have shown that hyperphosphatemia is associated with 
unexpectedly high rates of CV events and death in ESRD patients [94].
Hyperphosphatemia is a strong inducer of VC by inducing smooth muscle cells 
to undergo an osteochondrogenic phenotype change through a mechanism requir-
ing sodium-dependent phosphate cotransporters [11]. In a group of 43 patients 
receiving peritoneal dialysis studied by MDCT at baseline and after 1 year of follow-
up, Stompor and colleagues reported a significant correlation between changes 
in coronary calcium score and mean values of phosphate and calcium–phosphate 
product [95]. A study with uremic rats fed with high phosphate diet showed that 
aortic medial calcification could be blocked by treatment with the phosphate 
binder, sevelamer [96].
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Lowering serum phosphate levels with a non-calcium containing phosphate 
binder slows progression of VC in pre-dialysis and ESRD patients [97–99]. In pre-
dialysis patients, treatment with calcium carbonate did not enhance the progression 
of CAC, as it has been observed in patients on dialysis [97].
3.2.2.2 Oral calcium intake
In dialysis patients, the use of calcium-based phosphate binders is strongly associ-
ated with development and progression of CAC, due to the ingestion of large amounts 
of calcium and the consequent hypercalcemia [97]. Therefore, a positive calcium 
balance may increase the risk of calcium overload and CV calcification and it should be 
taken into account when calcium salts are prescribed. Discontinuation or dose reduc-
tion of calcium-based phosphate binders is suggested in the presence of hypercalce-
mia, CV calcification, adynamic bone disease, and/or low serum PTH levels [90].
Phosphate binding and lowering of serum phosphate can be achieved with 
calcium-based or non-calcium-based binders. A meta-analysis including 11 ran-
domized trials (4622 patients) showed that patients assigned to non-calcium-based 
binders had a 22% reduction in all-cause mortality compared with those assigned to 
calcium-based phosphate binders in patients with CKD [100].
3.2.2.3 Dialysate calcium
The exposure to high calcium concentrations may influence the development of 
low–turnover bone disease and CAC in HD patients. A randomized controlled study 
showed that lowering Ca exposure through dialysate (dialysate Ca concentration 
of 1.25 mmol/L vs. 1.75 mmol/L) attenuates progression of CAC and improves low 
bone turn-over in HD patients with baseline PTH levels ≤300 pg./ml [101].
3.2.2.4 Secondary hyperparathyroidism and adynamic bone disease
Both secondary hyperparathyroidism (SHPT) high-turnover renal osteodys-
trophy and adynamic bone disease have been associated with VC. In a group of 58 
ESRD patients on HD, bone-histomorphometry characteristics were compared with 
the arterial calcification (AC) scores. High AC scores were associated with bone his-
tomorphometry values, suggestive of low bone activity and adynamic bone disease. 
This indicates that therapeutic interventions associated with excessive decrease of 
parathyroid activity favors lower bone turnover and adynamic bone disease that, 
in combination with interventions that increase the Ca balance, could influence the 
development and progression of AC. [102]
3.2.2.5 Vitamin D and calcimimetic agents
A major complication of SHPT is renal osteodystrophy, in association with 
alterations in calcium and phosphorus metabolism leading to CV calcification. 
Active vitamin D compounds and calcimimetic agents are used to treat SHPT in 
dialysis patients. Untreated vitamin D deficiency has been associated with increased 
VC, in part due to accelerated development of atherosclerosis [103, 104]. In these 
patients, vitamin D supplement may have a protective benefit against VC by 
decreasing endothelial injury, inactivating renin-angiotensin-aldosterone system, 
decreasing insulin resistance, lowering cholesterol, inhibiting foam cell and choles-
terol efflux in macrophages, and modulating vascular regeneration [105]. Excessive 
administration of vitamin D has been also associated with increased VC, possibly 
related to hypercalcemia and an elevated calcium-phosphate product. Cinacalcet 
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has the ability to simultaneously lower PTH, calcium, phosphorus, and CaxP in 
patients with SHPT [106]. In a study, Cinacalcet plus low-dose active vitamin D 
derivatives attenuated vascular and cardiac valve calcification [107].
3.2.2.6 Hypomagnesemia and FGF-23
Hypomagnesemia has been associated with increased VC [23, 108, 109]. In a 
population with diabetes mellitus type 2 and mild to moderate CKD, hypomagne-
semia was found to be an independent predictor of mitral valve calcification and 
intima media thickness [110].
3.2.2.7 Oral vitamin K antagonists
The vitamin K-dependent MGP, despite not being related to blood coagulation 
cascade, is affected by Vitamin K antagonists (VKA) and is considered a strong 
inhibitor of calcification of arterial vessel wall and cartilage [111]. Warfarin (a VKA) 
is a risk factor for calcific uremic arteriolopathy, necrotizing skin condition observed 
in dialysis patients, associated with extremely high mortality rates [11, 112, 113].
3.2.3 Diabetes
Many studies have shown that diabetes is a risk factor for VC in patients without 
CKD. In patients with eGFR <60 mL/min/1.73 m2 who were not on dialysis, diabe-
tes also increased the risk of VC from 3.5 to 55.7% [114].
3.2.4 Dyslipidemia
Dyslipidemia increases the risk of VC in patients without CKD, via induction 
of inflammation and endothelial/vascular smooth muscle cell damage by oxidized 
lipids [115, 116]. Beneficial effects of sevelamer on VC may be related to its lipid-
lowering effects [99].
3.2.5 Other molecules
Serum Gla-Rich Protein (GRP) levels were found to progressively decrease 
from stage 2 to stage 4 CKD. A multivariate analysis study identified that 
decreased eGFR, low levels of GRP, and high levels of fibroblast growth factor-23 
(FGF-23) were associated with higher VC score and pulse pressure. These results 
indicate an association between GRP, renal dysfunction and CKD-mineral and 
bone disorder. The relationship between low levels of GRP and VC suggests a 
future potential utility for GRP as an early marker of vascular damage in CKD 
[117]. Once uremic CPPs and EVs are important players in the mechanisms of 
widespread calcification in CKD, GRP could have a role as an inhibitory factor, 
preventing calcification at systemic and tissue levels. Possible future approaches 
targeting the increase of γ-carboxylated GRP bioavailability could represent 
promising therapeutics [118].
3.3 Detection
The recognition of vascular or valvular calcification in patients with CKD stages 
G3a–G5D places them with highest cardiovascular risk [119]. The early diagnosis of 
VC and the identification of its cause raises hope for therapeutic intervention that 
might reduce CVD in patients with CKD.
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Various noninvasive methods, such as ultrasound, fluoroscopy, and digital 
subtraction angiography, have been used to detect and measure VC [28]. Currently, 
EBCT and multidetector computed tomography (MDCT) are excellent methods to 
detect and quantify VC [28], with their results being stronger predictors of a cardio-
vascular event in normal population [28, 119]. Bursztyn and colleagues reported 
a twofold greater progression in coronary calcium score (measured by MDCT) in 
hypertensive patients with CKD, than in hypertensive patients with normal renal 
function [120].
A number of noninvasive methods, which are more easily and available tech-
niques, can also be used to detect the presence or absence of valvular calcifica-
tion, like lateral abdominal radiograph and echocardiogram [119]. The simplest 
technique is plain radiography, which demonstrates pipe-stem calcification of the 
tunica media and more irregular, patchy calcifications of the internal elastic lamina. 
However, this is an insensitive method and does not quantify the severity of VC [8].
Several scores, based on plain radiographic imaging or CT scans, are used in 
clinical studies to calcium quantification and scoring:
• Agatston score - quantifies CAC detected by an unenhanced low-dose cardiac 
CT scan. The Agatston score allows for early risk stratification for a major 
adverse cardiac event.
• Adragão score – the Adragão score quantifies calcification of the iliac, femo-
ral, radial and digital arteries observed on plain radiographs of the hands and 
pelvis. The final value ranges between 0 and 8 points (0 to 4 in the pelvis and 
0 to 4 in the hands). VC score ≥ 3 had an almost fourfold higher risk of cardio-
vascular mortality, representing a simple and inexpensive tool for assessing the 
cardiovascular risk related to VC in HD patients [121].
In the Study of Mineral and Bone Disorders that included 742 patients with 
nondialysis CKD stages 3–5 from 39 centers in Spain, VC assessment using Adragão 
Score was independently associated with all-cause and cardiovascular mortality as 
well as a shorter hospitalization event–free period [122].
• Kauppila score – This score quantifies the severity of lumbar aortic calcifi-
cations observed on a lateral abdominal radiograph ranging from the T-10 
vertebra to the first two sacral vertebrae. A score of 1 to 3 is assigned based on 
extent of calcification (ie, one-third, two-thirds, or more than two-thirds of 
the vertebra).
3.4 Treatment
The approach to decrease the progression of VC can be influenced by treatment. 
Given that VC is associated with increased cardiovascular risk and the pathogenesis 
seems to be related to CKD-MBD abnormalities and atherosclerosis, the treatment 
should focus on the prevention of arterial lesions, correcting the several traditional 
and non-traditional pro-atherogenic risk factors responsible for arterial injury, 
mainly calcium and phosphate balance [5, 29].
Some experimental studies have suggested that the administration of magne-
sium prevents VC, not only reducing the deposition of calcium, but also inhibiting 
osteogenic transdifferentiation, and may be considered an important and realistic 
approach to potentially reduce the risk for VC and subsequent cardiovascular com-
plications in CKD patients. Clinical trials are warranted to further assess the clinical 
relevance of magnesium in this regard [123, 124].
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In patients with CKD G3a–G5D, decisions about phosphate-lowering treatment 
should be based on progressively or persistently elevated serum phosphate, as 
mentioned earlier [119].
In the management of moderate to severe secondary hyperparathyroidism, 
current treatment options consist of the oral administration of intestinal phosphate 
binders, oral or intravenous calcitriol or active vitamin D analogs, and the oral or 
intravenous calcimimetic agents (cinacalcet and etacalcetide) [125].
4. Conclusions
The high incidence of multiple traditional and non-traditional risk factors 
predisposes advanced CKD and dialysis patients to a considerable burden of CVD. 
This chapter has summarized the biology of VC, highlighting the processes of min-
eralization, the effects of local inflammation, and the available evidence about risk 
factors modification, prevention and screening in CKD. Clinicians must understand 
the limitations of the current evidence and adapt specific therapeutic strategies to 
the individual patient. Future research into modifiable, non-traditional risk factors 
with emphasis on mineral bone metabolism is warranted and we look forward to 
their clinical application and improvement of CVD outcomes in CKD patients.
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